MX2020003373A - Forma cristalina de hidrato de lorlatinib base libre. - Google Patents
Forma cristalina de hidrato de lorlatinib base libre.Info
- Publication number
- MX2020003373A MX2020003373A MX2020003373A MX2020003373A MX2020003373A MX 2020003373 A MX2020003373 A MX 2020003373A MX 2020003373 A MX2020003373 A MX 2020003373A MX 2020003373 A MX2020003373 A MX 2020003373A MX 2020003373 A MX2020003373 A MX 2020003373A
- Authority
- MX
- Mexico
- Prior art keywords
- free base
- crystalline form
- base hydrate
- lorlatinib free
- lorlatinib
- Prior art date
Links
- IIXWYSCJSQVBQM-LLVKDONJSA-N lorlatinib Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 title abstract 3
- 239000012458 free base Substances 0.000 title abstract 2
- 229950001290 lorlatinib Drugs 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570326P | 2017-10-10 | 2017-10-10 | |
| US201862727734P | 2018-09-06 | 2018-09-06 | |
| PCT/IB2018/057735 WO2019073347A1 (en) | 2017-10-10 | 2018-10-04 | CRYSTALLINE BASE FREE HYDRATE SHAPE OF LORLATINIB |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003373A true MX2020003373A (es) | 2020-10-12 |
Family
ID=64049474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003373A MX2020003373A (es) | 2017-10-10 | 2018-10-04 | Forma cristalina de hidrato de lorlatinib base libre. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11299500B2 (enExample) |
| EP (1) | EP3694863B1 (enExample) |
| JP (1) | JP7153069B2 (enExample) |
| KR (1) | KR102424621B1 (enExample) |
| CN (1) | CN111201235B (enExample) |
| AU (1) | AU2018349259B2 (enExample) |
| CA (1) | CA3077508C (enExample) |
| CY (1) | CY1126141T1 (enExample) |
| DK (1) | DK3694863T3 (enExample) |
| ES (1) | ES2952985T3 (enExample) |
| FI (1) | FI3694863T3 (enExample) |
| HU (1) | HUE062926T2 (enExample) |
| MX (1) | MX2020003373A (enExample) |
| PL (1) | PL3694863T3 (enExample) |
| PT (1) | PT3694863T (enExample) |
| RU (1) | RU2022109286A (enExample) |
| SG (1) | SG11202002445SA (enExample) |
| SI (1) | SI3694863T1 (enExample) |
| TW (1) | TWI775960B (enExample) |
| WO (1) | WO2019073347A1 (enExample) |
| ZA (1) | ZA202001661B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201913200XA (en) | 2015-07-31 | 2020-03-30 | Pfizer | Crystalline form of lorlatinib free base |
| CA3019905C (en) | 2016-04-08 | 2022-08-23 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
| WO2019209633A1 (en) * | 2018-04-23 | 2019-10-31 | Pliva Hrvatska D.O.O. | Solid state forms of lorlatinib and their preparation |
| US12391708B2 (en) | 2019-07-18 | 2025-08-19 | Tapi Croatia Industries Ltd | Crystalline Lorlatinib : fumaric acid and solid state form thereof |
| CN112321604A (zh) * | 2019-08-05 | 2021-02-05 | 华东理工大学 | 大环类jak2抑制剂及其应用 |
| EP4041396A1 (en) | 2019-10-10 | 2022-08-17 | Sandoz AG | Polymorph of lorlatinib |
| CN112824417A (zh) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | 一种劳拉替尼的制备方法 |
| TW202146017A (zh) | 2020-03-05 | 2021-12-16 | 美商輝瑞股份有限公司 | 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合 |
| CN111362967B (zh) * | 2020-04-28 | 2021-09-07 | 南京雷正医药科技有限公司 | 苯并氧杂二氮杂十四碳烯衍生物及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2796967C (en) | 2010-05-04 | 2015-12-01 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
| JP5808818B2 (ja) | 2010-11-25 | 2015-11-10 | ラツィオファーム・ゲーエムベーハー | アファチニブの新規塩及び多形形態 |
| PE20141639A1 (es) * | 2011-06-08 | 2014-11-08 | Biogen Idec Inc | Proceso para preparar fumarato de dimetilo de alta pureza y cristalino |
| CA2863892C (en) * | 2012-03-06 | 2016-08-30 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
| CA2916605C (en) | 2013-06-28 | 2018-04-24 | Pfizer Inc. | Solid forms of a macrocyclic kinase inhibitor |
| EP3183256A4 (en) * | 2014-08-20 | 2018-05-30 | Teligene Ltd. | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
| WO2016026423A1 (en) * | 2014-08-20 | 2016-02-25 | Teligene Ltd | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
| SG10201913200XA (en) | 2015-07-31 | 2020-03-30 | Pfizer | Crystalline form of lorlatinib free base |
| CA3019905C (en) | 2016-04-08 | 2022-08-23 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
-
2018
- 2018-10-04 SI SI201830952T patent/SI3694863T1/sl unknown
- 2018-10-04 AU AU2018349259A patent/AU2018349259B2/en active Active
- 2018-10-04 DK DK18795807.9T patent/DK3694863T3/da active
- 2018-10-04 FI FIEP18795807.9T patent/FI3694863T3/fi active
- 2018-10-04 MX MX2020003373A patent/MX2020003373A/es unknown
- 2018-10-04 CA CA3077508A patent/CA3077508C/en active Active
- 2018-10-04 EP EP18795807.9A patent/EP3694863B1/en active Active
- 2018-10-04 PT PT187958079T patent/PT3694863T/pt unknown
- 2018-10-04 US US16/650,505 patent/US11299500B2/en active Active
- 2018-10-04 CN CN201880065709.6A patent/CN111201235B/zh active Active
- 2018-10-04 JP JP2020520115A patent/JP7153069B2/ja active Active
- 2018-10-04 SG SG11202002445SA patent/SG11202002445SA/en unknown
- 2018-10-04 PL PL18795807.9T patent/PL3694863T3/pl unknown
- 2018-10-04 HU HUE18795807A patent/HUE062926T2/hu unknown
- 2018-10-04 RU RU2022109286A patent/RU2022109286A/ru unknown
- 2018-10-04 ES ES18795807T patent/ES2952985T3/es active Active
- 2018-10-04 WO PCT/IB2018/057735 patent/WO2019073347A1/en not_active Ceased
- 2018-10-04 KR KR1020207010512A patent/KR102424621B1/ko active Active
- 2018-10-05 TW TW107135186A patent/TWI775960B/zh active
-
2020
- 2020-03-17 ZA ZA2020/01661A patent/ZA202001661B/en unknown
-
2023
- 2023-07-25 CY CY20231100357T patent/CY1126141T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018349259B2 (en) | 2021-02-18 |
| PL3694863T3 (pl) | 2023-09-25 |
| TWI775960B (zh) | 2022-09-01 |
| AU2018349259A1 (en) | 2020-04-09 |
| JP7153069B2 (ja) | 2022-10-13 |
| DK3694863T3 (da) | 2023-07-03 |
| EP3694863A1 (en) | 2020-08-19 |
| TW201922753A (zh) | 2019-06-16 |
| CN111201235B (zh) | 2023-02-10 |
| WO2019073347A1 (en) | 2019-04-18 |
| US11299500B2 (en) | 2022-04-12 |
| HUE062926T2 (hu) | 2023-12-28 |
| SG11202002445SA (en) | 2020-04-29 |
| RU2020113141A (ru) | 2021-11-12 |
| PT3694863T (pt) | 2023-08-23 |
| EP3694863B1 (en) | 2023-06-21 |
| JP2020536893A (ja) | 2020-12-17 |
| ES2952985T3 (es) | 2023-11-07 |
| KR20200051781A (ko) | 2020-05-13 |
| ZA202001661B (en) | 2023-11-29 |
| US20200308191A1 (en) | 2020-10-01 |
| CA3077508A1 (en) | 2019-04-18 |
| BR112020005989A2 (pt) | 2020-09-29 |
| CA3077508C (en) | 2023-02-14 |
| CY1126141T1 (el) | 2023-11-15 |
| RU2020113141A3 (enExample) | 2021-11-12 |
| CN111201235A (zh) | 2020-05-26 |
| FI3694863T3 (fi) | 2023-08-18 |
| RU2022109286A (ru) | 2022-05-06 |
| SI3694863T1 (sl) | 2023-10-30 |
| KR102424621B1 (ko) | 2022-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202001661B (en) | Crystalline form of lorlatinib free base hydrate | |
| TN2016000529A1 (en) | Substituted dihydroisoquinolinone compounds | |
| MX389597B (es) | Inhibidores de cdk2/4/6 de piridopirimidinona. | |
| MX382600B (es) | Forma cristalina de base libre de lorlatinib. | |
| PH12017500367B1 (en) | Compounds that inhibit mcl-1 protein | |
| MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| MX2015011898A (es) | Compuestos de pirazolo y usos de los mismos. | |
| MX363347B (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| MX2020002924A (es) | Lactamas fusionadas de arilo y heteroarilo. | |
| UA109868C2 (ru) | Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar) | |
| WO2016065028A8 (en) | Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine | |
| PH12017501539A1 (en) | Disacetoxytubulysin h and analogs thereof | |
| TW201613864A (en) | Novel compounds | |
| NZ735736A (en) | Acetate salt of buprenorphine and methods for preparing buprenorphine | |
| WO2016100302A3 (en) | Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof | |
| SG10201805890QA (en) | Compositions and methods for treatment of abnormal cell growth | |
| TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| PH12016501997B1 (en) | Cycloalkyl-linked diheterocycle derivatives | |
| MX343234B (es) | Formas cristalinas de 6-(1h-imidazol-1-il)-2-fenilquinazolina. | |
| WO2014160143A3 (en) | Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders | |
| MX2015012600A (es) | Compuestos de tetrahidroisoquinolina-2-il-(quinazolina-4-il) metanona como inhibidores del crecimiento de células cancerígenas. | |
| NZ778505A (en) | Crystalline form of lorlatinib free base | |
| MX368381B (es) | Derivados de n-acilhidrazona para inhibidor selectivo de celulas t y farmacos anti malignidad linfoide. | |
| CA2905957C (en) | Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders | |
| HK1230956A1 (en) | Compositions and methods for treatment of abnormal cell growth |